Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Slovenia.
Center of Excellence in Environmental Toxicology, Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Steroids. 2014 Jan;79:49-63. doi: 10.1016/j.steroids.2013.10.012. Epub 2013 Nov 1.
Human aldo-keto reductases AKR1C1-AKR1C4 and AKR1D1 play essential roles in the metabolism of all steroid hormones, the biosynthesis of neurosteroids and bile acids, the metabolism of conjugated steroids, and synthetic therapeutic steroids. These enzymes catalyze NADPH dependent reductions at the C3, C5, C17 and C20 positions on the steroid nucleus and side-chain. AKR1C1-AKR1C4 act as 3-keto, 17-keto and 20-ketosteroid reductases to varying extents, while AKR1D1 acts as the sole Δ(4)-3-ketosteroid-5β-reductase (steroid 5β-reductase) in humans. AKR1 enzymes control the concentrations of active ligands for nuclear receptors and control their ligand occupancy and trans-activation, they also regulate the amount of neurosteroids that can modulate the activity of GABAA and NMDA receptors. As such they are involved in the pre-receptor regulation of nuclear and membrane bound receptors. Altered expression of individual AKR1C genes is related to development of prostate, breast, and endometrial cancer. Mutations in AKR1C1 and AKR1C4 are responsible for sexual development dysgenesis and mutations in AKR1D1 are causative in bile-acid deficiency.
人类醛酮还原酶 AKR1C1-AKR1C4 和 AKR1D1 在所有甾体激素的代谢、神经甾体和胆汁酸的生物合成、共轭甾体的代谢以及合成治疗性甾体中发挥着重要作用。这些酶催化甾体核和侧链上 C3、C5、C17 和 C20 位置的 NADPH 依赖性还原。AKR1C1-AKR1C4 在不同程度上充当 3-酮、17-酮和 20-酮甾体还原酶,而 AKR1D1 则是人类中唯一的 Δ(4)-3-酮甾体-5β-还原酶(甾体 5β-还原酶)。AKR1 酶控制核受体的活性配体的浓度,并控制其配体占据和转录激活,它们还调节可以调节 GABAA 和 NMDA 受体活性的神经甾体的数量。因此,它们参与核受体和膜结合受体的受体前调节。个体 AKR1C 基因的表达改变与前列腺癌、乳腺癌和子宫内膜癌的发展有关。AKR1C1 和 AKR1C4 的突变导致性发育不良,AKR1D1 的突变导致胆汁酸缺乏。